Fortress Biotech Forms New Gene Therapy Subsidiary

Fortress Biotech (NASDAQ:FBIO) announced the creation of a new subsidiary called Aevitas Therapeutics, which will develop novel gene therapy approaches for complement-mediated diseases.

As quoted in the press release:

The proprietary technology, licensed from a leading university, uses adeno-associated virus (AAV)-based gene therapy to restore lasting production of functional complement regulatory proteins, providing a potentially curative treatment.

Irregularities in these proteins can play a vital role in an array of complement-mediated diseases, including atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH). Recent research has suggested that complement regulatory proteins could also play a key role in the pathogenesis of age-related macular degeneration.

Click here to read the full press release.

Get the Latest Genetics Investing Stock Information

Get the latest information about companies associated with Genetics Investing delivered directly to your inbox.

By selecting company or companies above, you are giving consent to receive email from those companies. And remember you can unsubscribe at any time.

2018 Genetics Market Report

Find out what to watch for in the world of genetics investing.


Leave a Reply